In Detail

Michael Schlander

Professor of Health Economics at the University of Heidelberg / Germany, and Head of the Division of Health Economics at the German Cancer Research Center (DKFZ), Heidelberg / Germany (since January 2017)


Foundation Chairman & Scientific Director of the independent Institute for Innovation & Valuation in Health Care (InnoValHC), a not-for-profit, non-partisan scientific organization dedicated to research related to the utilization, effectiveness, efficiency, and quality of health care, with particular emphasis on novel approaches of service provision and evaluation (since June 2005)

Prof. Michael Schlander

Academic Roles

Prior Academic Roles

  • Professor of Business Administration and (Technology, Innovation, Life Sciences & Health Care) Management (September 2002 – December 2016; position offered in January 2002, accepted: February 2002) at the University of Applied Economic Sciences (Hochschule für Wirtschaft), Ludwigshafen am Rhein / Germany; focus on health economics, health care management, and innovation management; inauguration of a new international study program in innovation management (leading students to the degree of Master of Arts, M.A.)
  • Health Economist at the University of Heidelberg / Germany, Mannheim Institute of Public Health, Social and Preventive Medicine (2007-2016)
  • Member of Scientific Course Committee, Postgraduate Program in Pharmaceutical Medicine, responsible for courses in health economics and innovation management at the University of Duisburg-Essen / Germany (2005-2008); before that, founding member of Scientific Course Committee, Postgraduate Program in Pharmaceutical Medicine, and Member of Faculty of Medicine, University of Witten/Herdecke / Germany (1996-2005)

Selected Academic Offers

received during tenured professorship at University of Applied [Economic] Sciences Ludwigshafen, but not accepted:

  • January 2011
    Full Professorship (“W3”) for Health Economics
    (at the Mannheim Medical Faculty of the University of Heidelberg)
    listed primo loco
  • April 2009
    Head of Health Economics Department
    (for a major official HTA Agency in Europe)
  • June 2008
    Worldwide Vice President, Health Economics, Market Access & Pricing
    (for a top-10 research-based pharmaceutical corporation)
    position directly reporting to the Board of Management

Academic Background

  • Scientific Program Committee Chair
    of ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 15th Annual European Congress in Berlin, Germany, November 3-7, 2012

    [The ISPOR Annual European Meetings are the most important convention of health economists and health care policy makers in Europe. The Berlin conference was attended by more than 3,500 delegates and saw a record submission of close to 2,000 scientific presentations.]

  • "Habilitation" (venia legendi, Ph.D. equivalent)
    in Health Economics,
    University of Heidelberg / Germany
    November 2007
  • Diploma in Health Economics,
    Stockholm School of Economics / Sweden
    (Handelshögskolan i Stockholm),
    June 2002
  • Master of Business Administration (M.B.A.),
    City University of Seattle / Washington / U.S.A.
    (Valedictorian of the class of 1994)
  • Dr. med. (M.D.),
    University of Frankfurt am Main / Germany
    (Dissertation in experimental brain research;
    grade "summa cum laude"), January 1987
  • Licensed as a physician in Germany,
    since November 1985
Academic Prizes and Awards
  • ISPOR Distinguished Service Award for acting as ISPOR 15th Annual European Congress Program Chair, Berlin, Germany, November 2012
  • Best Contributed Poster Presentation Award (out of ~750 presentations) at the 8th Annual European ISPOR Congress, Florence, Italy, November 2005

Major Areas of Scientific Interest

Please refer to “Research” and to “Institute for Innovation & Valuation in Health Care”.

Presentations & Publications

Michael Schlander’s scientific presentations & publications focused predominantly on the fields of experimental brain research, innovation and technology management, strategic management, health care management, health economics, and health policy, including Health Technology Assessment. More than 500 scientific contributions to international meetings and journals have been documented in periodicals,

including (in alphabetical order):

  • ADHD – Attention Deficit Hyperactivity Disorders
  • American Journal of Psychiatry
  • Anatomy & Embryology
  • Annals of Haematology
  • Applied Clinical Trials
  • Brain Research
  • Cell and Tissue Research
  • Child and Adolescent Psychiatry and Mental Health (CAPMH)
  • Current Medical Research & Opinion
  • Current Pharmaceutical Design
  • Drug Information Association (DIA) Global Forum
  • Drug Information Journal
  • European Child and Adolescent Psychiatry
  • European Journal of Clinical Chemistry & Clinical Biochemistry
  • European Journal of Psychiatry
  • Expert Reviews in Pharmacoeconomics and Outcomes Research
  • Gastroenterology
  • Gut
  • Health Affairs
  • Health Services Research
  • International Journal of Clinical Pharmacology and Therapeutics
  • ISPOR Connections
  • JAMA Psychiatry
  • Journal of Clinical Anesthesia
  • Journal of Comparative Effectiveness Research
  • Journal of Market Access & Health Policy
  • Journal of Medical Ethics
  • Journal of Public Health
  • Neuroscience
  • Neuroscience Letters
  • Orphanet Journal of Rare Diseases
  • Pharmaceutical Executive
  • Progress of Clinical & Biological Research
  • Value in Health

as well as a number of German periodicals, such as

  • Ärztliches Labor
  • Deutsches Ärzteblatt
  • Gesellschaftspolitische Kommentare
  • Gesundheitsökonomie & Qualitätsmanagement
  • Kassenarzt
  • Medizinische Klinik
  • Münchner Medizinische Wochenschrift (MMW) / Fortschritte der Medizin,
  • Nervenarzt
  • Nieren- und Hochdruckkrankheiten
  • PharmInd – Die pharmazeutische Industrie
  • psychoneuro
  • Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen (ZEFQ)

A complete list of publications will be provided on request.

For further information on some publications of general interest, please also refer to “Publications” and to “Presentations”.

Membership in Scientific Associations

Michael Schlander has been a member of numerous scientific and professional associations, including the following:

  • International Health Economics Association (iHEA)
  • International Society for Pharmaoeconomics and Outcomes Research (ISPOR)

    [Michael Schlander served as scientific chair of the 15th Annual European ISPOR Congress in Berlin / Germany, November 03-07, 2012]

  • Product Development & Management Association (pdma)
  • Drug Information Association (DIA)
  • Association of German speaking economists (Verein für Socialpolitik)
  • Alliance for the Advancement of Applied Health Economics (A3HE)
  • German Society for Health Economics (DGGOe)

    [Michael Schlander was one of the 17 German university professors who founded the DGGOe at a meeting in Berlin / Germany, October 17, 2008.]

  • German Society for Pharmaceutical Medicine (Deutsche Gesellschaft für Pharmazeutische Medizin, DGPharMed)
  • Association of Medical & Scientific Journalists (Verband der Medizin- & Wissenschaftsjournalisten, VMWJ)
  • Frankfurt Medical Society (Frankfurter Medizinische Gesellschaft, FMG)

Professional Background

Professional experience gathered in Germany, Belgium, Switzerland, and the United States of America:

  • Professor of Health Economics

    University of Heidelberg and German Cancer Research Center
    (since January 2017)
  • Professor of Business Administration and Management
    (Focus on Health Care & Innovation Management)

    University of Applied Economic Sciences / Hochschule (für Wirtschaft) Ludwigshafen am Rhein
    (September 1, 2002 – December 31, 2016)

    Member of commission for "Good Scientific Practice"
  • Managing Director

    Biopharmaceutical & Medical Device Industry (Germany)
    (August 1, 1999 – August 31, 2002)

    Turn around and strategic change management;
    achieving sustained double-digit organic growth and double-digit return on revenues after a long-standing decline of market share, shrinking sales and substantial loss prior to taking over leadership
  • Strategic & International Marketing / Business Unit Leadership

    Biopharmaceutical Industry (Germany, Belgium, and United States)
    (September 1, 1993 – July 31, 1999)

    Inter alia, building, from scratch, a worldwide operating Strategic Business Unit (“Gastroenterology; responsibility for functional areas including project management, clinical development, international medical communications, international marketing, domestic marketing & sales management); leading one of the most successful new product launches of the German pharmaceutical industry (pantoprazole)
  • Clinical Research and Development

    Biopharmaceutical Industry (Germany and Switzerland)
    (September 1, 1987 – August 31, 1993)

    Leading successful European new product development programs
    (in cardiovascular medicine, immunology, supportive cancer care)
  • Experimental Brain Research and Clinical Neurology

    (April 1, 1982 - August 31, 1987)

    Universities of Frankfurt am Main and Mainz (Germany)

    Combined light and electron microscopic studies of identified neurons in the hippocampus of the mammalian and the human brain (including M.D. thesis project); clinical residency in neurology.